AZ: positive CHMP for Tagrisso first-line nsclc
27 April 2018 12:30 BST TAGRISSO RECEIVES POSITIVE EU CHMP OPINION FOR 1ST-LINE TREATMENT OF EGFR-MUTATED NON-SMALL CELL LUNG CANCER Recommendation based on FLAURA trial data showing unprecedented median progression-free survival of 18.9 months for Tagrisso versus 10.2 months compared with current standard of care The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending a change to the terms of the Marketing Authorisation for Tagrisso (osimertinib) to include the 1st-line treatment of